# A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors

> **NCT05074472** · PHASE1,PHASE2 · COMPLETED · sponsor: **ZielBio, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Solid Tumor, Adult
- Pancreatic Ductal; Adenocarcinoma
- Ovarian Serous Adenocarcinoma
- Biliary Cancer Metastatic
- Ovarian Serous Cystadenocarcinoma

## Interventions

- **DRUG:** ZB131

## Key facts

- **NCT ID:** NCT05074472
- **Lead sponsor:** ZielBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-14
- **Primary completion:** 2023-08-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05074472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05074472, "A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05074472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*